Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence
- PMID: 33375920
- PMCID: PMC7879226
- DOI: 10.1177/1358863X20974452
Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence
Keywords: arteriovenous malformation; cerebral; hereditary hemorrhagic telangiectasia (HHT); pulmonary; rare diseases; screening.
Conflict of interest statement
References
-
- Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: A population-based study of prevalence and mortality in Danish patients. J Intern Med 1999; 245: 31–39. - PubMed
-
- Donaldson J, McKeever TM, Hall IP, et al. The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: A population-based study. Thorax 2014; 69: 161–167. - PubMed
-
- Guttmacher AE, Marchuk DA, White RI., Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333: 918–924. - PubMed
-
- Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48: 73–87. - PubMed
-
- Hosman AE, de Gussem EM, Balemans WA, et al. Screening children for pulmonary arteriovenous malformations: Evaluation of 18 years of experience. Pediatr Pulmonol 2017; 52: 1206–1211. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
